Table 4 In vivo anti-cancer activity of identified GpM components

Gypenosides

Nude mice: xenografted with human oral cancer SAS cells

65.76 % (tumor size, 20 mg/kg for 28 days)

[89]

Gypenosides

BALB/c mice: injected with human leukemia WEHI-3 cells

150 % (survival rate, 2 mg/kg for 2 weeks)

175 % (survival rate, 4 mg/kg for 2 weeks)

[90]

Gypenosides

Nude mice: xenografted with human leukemia HL-60 cells

44 % (tumor size, 20 mg/kg for 28 days)

[91]

Gypenosides

BALB/c mice: xenografted with murine S180 sarcoma cells

39.57 % (tumor size, 30 mg/kg for 4 days)

[92]

Gypenosides

BALB/c mice: xenografted with murine colorectal cancer CT-26 cells

75 % (tumor size, 25 mg/kg for 19 days)

55 % (tumor size, 50 mg/kg for 19 days)

26 % (tumor size, 50 mg/kg + 5 mg/kg 5-Fu for 19 days)

[93]

Gypenosides

Apc ^Min/+ mice: intestinal neoplasia model

66.06 % (polyps number, 500 mg/kg for 4 weeks)

59.92 % (polyps number, 750 mg/kg for 4 weeks)

[94]

Gypenosides

Apc ^Min/+ mice: intestinal neoplasia model

59.32 % (polyps number, 500 mg/kg for 8 weeks)

[95]

Polysaccharide

BALB/c mice: xenografted with murine S180 sarcoma cells

62.77 % (tumor size, 100 mg/kg for 14 days)

59.24 % (tumor size, 200 mg/kg for 14 days)

[97]

Polysaccharide

ICR mice: xenografted with mouse hepatoma H22 cells

62.89 % (tumor size, 50 mg/kg for 10 days)

49.22 % (tumor size, 200 mg/kg for 10 days)

[20]